

PREDICTMEDIX

AI-Powered Rapid Health Screening Solutions for Workplace Safety and Healthcare

PREDICTMEDIX.COM

CSE : PMED OTCQB : PMEDF



Forward Looking Statements Disclaimer


Predictmedix Inc. (the "Company") is a reporting issuer under the Securities Exchange Act of 1934 (the "34 Act"). Further information about the Company is available at the SEC's EDGAR website at: <https://www.sec.gov/edgar/browse/?CIK=1878079&owner=exclude> This presentation is qualified by the Company's more expansive disclosure contained in its '34 Act filings, particularly the section entitled "Risk Factors". The Company will not update this presentation but continues to present more current information in its '34 Act filings. This presentation may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."



Predictmedix Overview

Predictmedix is an emerging provider of rapid health screening, medical devices, and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and identify symptoms of infectious diseases such as COVID-19, drug or alcohol impairment, and mental illnesses.

- **Contactless, Non-Invasive Screening:** Rapid screening process, similar to walking through a metal detector, utilizes AI to assess unique physiological patterns of diseases or impairments in seconds – maintaining workplace productivity.
- **Significant Addressable Market:** Safe Entry Stations have been successfully deployed at offices, long-term care centers, industrial workplaces & large events.
- **Validation by Tier-1 Customers:** India Oil Corporation, with 33,000 employees worldwide, is evaluating the Safe Entry Station for a global rollout.
- **High-Margin, Recurring Revenue Model:** Screening as a Service (SaaS) model with recurring monthly revenue, software-like margins and multi-year contracts.
- **Remote Patient Care Platform:** Additional optionality to leverage AI tools and wearables to create a data-enabled remote monitoring telehealth platform.



Predictmedix	
CSE: PMED - OTCQB: PMEDF	
Share Price ¹	\$0.11
Market Cap ¹	\$12M
Quarterly Cash Usage	\$0.4M
Cash ²	\$300k
Debt ²	\$0
Shares Outstanding	108.8M
Headquarters	Toronto, CAN

1. As of March 10, 2022
2. As of March 10, 2022

Predictmedix is fully reporting in the US and is 20-F compliant.



The Current Landscape

Infectious Diseases

Cannabis & Alcohol Impairment and Extreme Fatigue

Mental Illnesses


Triage Solution & Virtual Care

Fit for Duty Screening Solutions



SAFE ENTRY STATION

Powered By PREDICTMEDIX



Fit for Duty: a complete, autonomous, non-invasive workplace screening solution for industries around the globe

Construction. Mining. Warehouses. Manufacturing. Corporate Offices. And more.

Predictmedix's Fit For Duty screening solutions are a complete solution for industries around the world where employee safety and productivity are top priority.

- **Infectious Diseases**
- **Impairment from cannabis & alcohol**
- **Extreme Fatigue**
- **Mental Health**

Many laws restrict employers to test for drugs on a regular basis. Additionally, drug testing isn't an affordable solution, and does not test for actual impairment.

Predictmedix's **Fit for Duty** screening solutions is cost-effective, accurate, autonomous, and non-invasive, providing accurate screening that can be used on site daily, with instant results.

1

Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated



Screening for Symptoms of Infectious Diseases

Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and then make a determination as to the probability of that person being infected or not infected. Real time assessment will indicate whether follow-up testing is needed.

As the virus mutates, our AI will learn how new symptoms present new patterns from which to continue detecting infection.

Predictmedix is critical even after an effective, safe vaccine has successfully been deployed to at least 80% of the global population in the coming years as annual flu and other infectious diseases proliferate.

1

Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated

Independent clinical study is currently underway at North American Hospital

Clinical validation will provide Predictmedix with the ability to receive FDA Medical Device Certifications as part of commercialization plan.

Easy to deploy in any indoor and outdoor location

Workplaces, Retail, Institutions, and Buildings.



Screening for Cannabis & Alcohol Impairment

Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired.

Without the ability to determine impairment, it is impossible to accurately predict safety risk, particularly for employees operating heavy machinery – which is ever more important as cannabis is now legal in many states and medically prescribed.

Rather than test for traces of potentially harmful substances, Predictmedix uses multispectral recognition technologies and AI to screen for true impairment from these substances.

1

Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated

Independent clinical study is currently underway at North American Hospital

Predictmedix first-to-market AI product screens for Cannabis and Alcohol impairment and is currently being tested and validated at a North American Hospital.

The Predictmedix AI model is being expanded to include screening for alcohol and opioids.

Third party validation and clinical study will allow Predictmedix to receive FDA Medical Device Certification as part of commercialization plan.



Cannabis & Alcohol Impairment Screening

Competitive Landscape

Company	AI	Non-Invasive	Impairment Detection	Notes	Commercialization Stage
	✗	✗	✗	Breathalyzer	Pre-commercialization
 HOUND LABS	✓	✗	✓	Unknown how it determines impairment and may rely on amount of cannabinoids to apply a rating for potential impairment similar to alcohol breathalyzer tests	Pre-commercialization
	✓	✓	✓	Non-invasive screening that uses machine learning AI models to assess impairment unique to each individual	Product Development



Mental Illness Diagnostic Screening

Predictmedix believes its technology may be expanded in the future to enable screening for certain mental illnesses. Mental illness is difficult to detect at early stages, primarily due to a lack of diagnostic tools other than standardized surveys and subjective assessment from trained healthcare practitioners.

Predictmedix will expand its current AI technology to use multispectral image patterns to effectively determine signs of mental illnesses, including depression, dementia and Alzheimer's.

Predictmedix deployed in healthcare facilities and medical offices will provide practitioners with a simple, measurable diagnostic tool to detect signs of these disorders at early stages.

First Diagnostic Tool

Predictmedix Mental Illness Diagnostic Screening will be a disruptive AI technology that will be the first solution of its kind to give healthcare practitioners the opportunity to provide proper care before their patients' condition worsens.

Predictmedix's relationships with healthcare organizations will allow for specific data collection to develop their Mental Illness Diagnostic Screening.



FDA Medical Device Classification for Infectious Diseases and Impairment Detection Solutions

Clinical studies are underway at a North American Hospital where Predictmedix's infectious diseases and impairment detection solutions are being clinically evaluated, fulfilling a prerequisite for certification with the U.S Food and Drug Administration (FDA).

The results of the study will be published in a peer-reviewed medical journal. Predictmedix has engaged an accredited consulting firm to assist the Company in seeking classification of the technology as a Class II Medical Device in the United States.

Clinical studies underway at North American Hospital

Independent study for infectious diseases symptom detection and impairment detection solutions in a clinical setting to provide additional third-party validation; prerequisite ahead of planned FDA Certification as class II medical device.



Safe Entry Stations are CE Mark and ISO Certified

The **CE mark** declares the conformity of the Safe Entry Station with EU regulations and indicates that a product has been assessed by the manufacturer and deemed to meet EU safety, health and environmental protection requirements.

ISO 13485 is the medical device industry's most widely used international standard for quality management.

Predictmedix is proud to develop and manufacture a product that meets performance, quality, and safety requirements.



Research & Development for AI-powered Medical Devices

Predictmedix's R&D strategy focuses on developing AI-powered medical devices for healthcare, workplace, law enforcement, public spaces, and more.

Predictmedix's AI algorithms are constantly improving and the potential to train the AI engine for multiple diseases and other uses means Predictmedix is positioned for a successful pipeline of medical devices that encompasses many uses.



Building value through AI-powered medical devices that can save lives

Predictmedix is dedicated to researching & developing novel methods of Healthcare screening by combining artificial intelligence and high-powered medical sensors.

Predictmedix and data partners are collecting data and training AI algorithms to develop medical devices for Healthcare and other industries.



Leading organizations and healthcare facilities are adopting or testing Safe Entry Stations



MGM Healthcare
Hospitals



Paras Defence & Space
Technologies



Indian Oil Corporation
Office Facilities

Sparta Health Inc

Sparta Health
Healthcare Clinics



Optima Living
Seniors Residences



ICFF Film Festival
Public Event



Flow Water
Manufacturing Facilities



Yorkdale Martial Arts
Exercise Facilities



Juiceworks
Manufacturing & Warehouse Facilities



Formula 1 Championship Racing
Public Event



Aspen Properties
The Edison The Ampersand
The Palliser Square Edmonton Bell Tower
Calgary Towers



Safe Entry Station Financial Model

Screening as a Service (SaaS) drives:

- High-Margin Revenue
- Recurring Revenue
- Multi-Year Contracts



Hardware Deployment
\$3,500 – 12,000/Unit

Safe Entry Station fabricated by strategic partners, with gross profit margins of 30-50% depending on regional supply chains.



Recurring SaaS Fee
\$1,000 – 3,000/month

Screening as a Service (SaaS) pricing per unit based on volume of screenings, providing predictable, high-margin revenue.



Multi-Year Contracts

Our customers invest in our technology not as a reaction to COVID, but with the long-term understanding that public health will never be viewed the same way and that detecting infectious diseases or drug and alcohol impairment in the workplace has significant value.



Tier-1 Global Reseller Partnerships

The biggest and best believe in our solutions

Capital-light commercial model leverages immense reach of our tier-1 partners, while keeping operating costs low to minimize burn.



Tech Mahindra

Predictmedix has signed Joint Venture agreements with Tech Mahindra, who will resell Predictmedix to their global client base, having already participated in a successful pilot test with our team.

Top 15

GLOBAL IT COMPANIES BY FORBES

\$4.9B

COMPANY OWNED BY MAHINDRA GROUP, A \$420.7BN FEDERATION OF COMPANIES

JUICEWORKS



CONNECTUS



North American Resellers

- Juiceworks Exhibits
- SBL Testing Technologies
- ConnectUs Global

European Resellers

- Taurus Medical (U.K.)

Caribbean Resellers

- Caribbean Digital Media Academy



Paras Defence

Predictmedix secured a reseller agreement with Paras Defence, an Indian defense contractor, who will fabricate and sell the Company's products within the South Asian market.

India's Most Progressive Defense Company

Significant Public Sector Reach

Defense contractor leveraging established public sector relationships throughout Asia






Safe Entry Station "PredictMedix" inauguration Indian Oil Corporation (IOCL)



Predictmedix Inc. and Juiceworks Provide Safe Entry Solutions to Facility Managers at IFMA World Workplace in Texas

PUBLISHED SEP 3, 2020 8:00AM EDT



by @accesswire on 26 Jun 2020, 08:01

Predictmedix and Tech Mahindra to Offer AI Based Healthcare Solution for Post COVID-19 Environment

Mainstream, trade, and investor media are actively pursuing Predictmedix for interviews and features.



Triage Solution for Hospitals – AI powered Health Screening

The current method of collecting incoming patient data in hospital settings is cumbersome, time-consuming, and a nightmare for nurses and doctors.

Predictmedix is developing an AI powered Triage Screening Solution to help Health Care Workers make quicker, important decisions for their patients.

Incoming patients will be autonomously scanned by Sensors, Multispectral, and RGB cameras that pick-up key data that is analyzed in real-time to provide nurses with patients' key vitals to determine next steps.

1


Quick, non-invasive, contactless screening for incoming patients' key vitals

2

Fully automated without the need for personnel to operate

3

Allows nurses and HCW to increase productivity and provide quicker care to patients who need it most



Data collection at multiple hospitals underway to develop Triage Screening Solution

Predictmedix is collecting patient data to refine and train the AI algorithms to accurately screen key vitals to help nurses and doctors make quicker, important decisions for their patients.

Mobile Wellbeing Remote Care Platform

Remote patient monitoring & Telehealth platform for healthcare, LTC, and employers

Predictmedix has acquired Mobile Wellbeing (MWB) to provide screening clients with an end-to-end solution, and to leverage a rapidly growing market for remote care in hospital settings as well as for specific high value sectors, including:

Long Term Care (LTC) and Retirement Residences

Covid-19 has revealed the devastating shortfalls in elder care that can be addressed by MWB's tools, giving families transparency of care being delivered to their loved ones

Clinical Research Organizations (CRO)

Traditional methods of on-site monitoring for clinical studies of medicines and vaccines has been greatly obstructed due to the current pandemic, and can be better managed using MWB to provide rigorously detailed virtual oversight and compliance

Large Scale Employees

Existing human resource platforms cannot provide managed return-to-work programs for employees diagnosed with Covid-19 or other infectious diseases, which can be best facilitated through MWB's integration with PredictMedix Screening Products or as a stand-alone tool



Intellectual Property Portfolio

Protecting our Technology in Key Global markets

6 U.S. PATENTS HAVE BEEN FILED

IMPAIRMENT (1)

INFECTIOUS DISEASE SYMPTOMS (1)

MOBILE WELLBEING (4)

Predictmedix Science Based Technology to Identify Persons Exhibiting Symptoms of Covid-19 and Other Infectious Diseases

July 6, 2020

Predictmedix is developing a proprietary Artificial Intelligence (AI) technology (patent pending) to identify persons who are presenting science-based symptomatic evidence of Covid-19, as well as other infectious diseases including Influenza.

The AI powered technology utilizes multispectral imaging cameras and ancillary sensors as data collection sources. These cameras and sensors provide the Predictmedix AI Covid-19 & Infectious Disease Screening Model with visual spectral imaging plus infrared thermography that falls outside of visual spectrum wavelengths. This data is processed using a Cloud/Edge configuration comparing, in real time, the complex thermographic patterns of persons being screening with learned data sets from healthy control groups and Covid-19 patients.

The result is an evidence-based determination that outputs a probability of infection or no infection. Built as an AI machine learning system, the Model continuously evolves as more data is received through screenings and from testing partners providing the most recent physiological patterns associated with symptoms of the virus. These include currently known symptoms of fatigue, headache, coughing, congestion, difficulty breathing and fever, which in turn have identifiable features based on blood flow, sweat gland activation, eye redness and other physiological processes.

As demonstrated by several studies, physiological patterns can be identified through multispectral cameras, and when used in proper combination can be used to assess the probability of an individual exhibiting symptoms associated with Covid-19 infection.

The utility of thermal imaging in identification of headaches has been explored in several studies over the past forty years. In 1997, Ford et. al. reviewed thermograms of 993 suitable patients with migraine with and without aura, chronic daily headache, cluster headache, posttraumatic headache, and a variety of other headache types.¹

Eight hundred fifty-five (86.1%) had abnormal thermograms usually characterized by decreased supraorbital thermal emission. Six hundred ninety-four (69.9%) of 993 had migraine without aura of whom 593 (85.4%) had abnormal thermograms. Two hundred two (20.3%) of 993 had migraine with aura, of whom 180 (89.1%) had abnormal thermograms. Thirty of 35 (85.7%) patients with cluster headache, and 28 of 33 (84.8%) with posttraumatic headache had abnormal thermograms. Twenty-four of 29 (82.8%) of patients with various less common headaches and head pain syndromes had abnormal thermography. The study concluded infrared thermography as being a useful diagnostic test in the management of headaches.

¹ Ford RG, Ford KT. Thermography in the diagnosis of headache. *Semin Neurol.* 1997;17(4):343-349. doi:10.1055/s-2008-1040947.

Page 1 of 3

Similarly, thermal imaging has also been explored as a tool for identification of nasal congestion. Moreover, studies have reported thermography as a better tool than X-rays in diagnosing frontal and ethmoidal sinusitis and as good as X-ray PNS and nose in diagnosing maxillary sinusitis.²

Ocular abnormalities consistent with keratoconjunctivitis³, commonly referred to as pink eye, as well as conjunctival hyperemia, chemosis, epiphora, or increased secretions⁴, have been shown to occur in patients with Covid-19.

Breathing function consists of inspiration and expiration cycles during which heat exchanges occur. Thermal images generate a periodic or quasiperiodic thermal signal in between high (expiration) and low (inspiration) values. This imaging system at a distance, achieving an accuracy of

is usually positioned near the nostrils to capture this breath signal. Thermal imaging behaves therefore as a non-invasive process, but at a distance. The estimation of breathing function is as proved by comparison with respiratory ground-truth [47,48]. Murthy et al⁵ found a high degree of chance correlation between the thermal and mechanical recordings over the same time period.

Thermal imaging and thermal imaging to monitor the breathing function of the nose and mouth detection through a cascade classifier. The tracking of these regions over time. ROI's coordinates were determined in thermal video. In terms of breathing rate estimation, the proposed method and the Bland-Altman plot with 95% confidence interval [39].

Thermal imaging in several studies to be a reliable way for estimating breathing function technology for screening symptoms associated with COVID-19.

Thermal imaging performance that includes both an increase in the breathing rate and an eventual inability to produce this force.

² Thermography in the Diagnosis of Chronic Sinusitis. *Cureus.* 2019;11(9):e2298. doi:10.7755/cureus.2298. ³ <https://doi.org/10.1001/jamaophthalmol.2020.1291> ⁴ Findings of Patients With Coronavirus Disease 2019 (COVID-19) in the Emergency Department. *JAMA.* 2020;323(12):1239-1240. doi:10.1001/jama.2020.1291 ⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ²¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ²² <https://doi.org/10.1109/JTE.2006.25.57-67> ²³ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ²⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ³¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ³² <https://doi.org/10.1109/JTE.2006.25.57-67> ³³ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ³⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁴⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁵⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁶⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁷⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁸⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹² <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹³ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ⁹⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁰⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹¹⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹²⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁷ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁸ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹³⁹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴⁰ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴¹ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴² <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴³ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴⁴ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴⁵ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴⁶ <https://doi.org/10.1109/JTE.2006.25.57-67> ¹⁴⁷ [https://doi.org/10.1](https://doi.org/10.1109/JTE.2006.25.57-67)

Leadership Team



Sheldon Kales

Director

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah

Interim CEO

- PhD, Banting Fellow (one of 23 global recipients in medicine)
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Rakesh Malhotra

CFO

- CPA designation in US and Canada, FCA
- Over 25 years in accounting, financing and internal controls
- Has held senior management positions in publicly traded companies



Nandan Mishra

Co-AI Lead

- Artificial Intelligence pioneer in translational research for AI
- Masters in Systems Biology and Bachelors Degree in Engineering from the Indian Institute of Technology
- Member of the prestigious National Mission of Interdisciplinary Cyber Physical Systems of India (a federal technology think tank)



Himanshu Ujjawal Singh

Co-AI Lead

- Specialization in Data Analytics and AI
- Consulted with several multinational corporations in setting up their analytics practice in the field of telecom, healthcare, retail and workforce analytics
- Expertise in data monetization



Rajiv Muradia

VP, Technology

- Mobile Wellbeing Founder
- Executive entrepreneur with experience in technology, management and business development
- Rajiv has successfully founded several companies and has helped a number of start-ups with their product strategy, positioning and technology visions



Board of Directors



Sheldon Kales

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah

- PhD, Banting Fellow
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Ajit Kumar

- Seasoned healthcare business leader
- Founder of K-Med Ltd.; among the largest suppliers of healthcare and medical equipment in the UK with operations in the Middle East, EU and Africa



Tomas Sipos

- Seasoned investment banker
- Has held several senior positions, including VP, Mergers and Acquisitions of Ernst & Young, Managing Director of Investment Banking at European Privatization & Investment Corporation and Senior Investment Banker for the International Finance Corporation
- Presently, CFO for Pistil Partners Inc., and serves as a director of NATO Association of Canada Program Committee



Advisory Board

Kapil Raval

Advisory Board Chair
Director of AI, Business Development, Microsoft

Global Business Leader with 25+ years experience. Kapil is currently a director at Microsoft, driving business development for AI solutions for different industries globally.

Having worked for global organizations like Philips, DEC, Compaq and HPE and Microsoft in Americas, Middle East and APJ, Kapil brings understanding of global cultural and market nuances, inventiveness and problem-solving skills.

Prabhakar Srivastava

Business Development

Senior Healthcare Executive with over 38+ years experience including CEO of an Indo-Israeli Venture. Mr. Srivastava has been pivotal in launching state-of-the-art innovative solutions for indigenous production through Transfer of Technology in healthcare & environment fields from companies including Phillips Medical Systems, Picker International Inc, Elscint Ltd., Medison Co. Ltd. and Toshiba Corporation.

Additionally, he has served as advisor to several African Countries viz. Uganda, Republic of Burundi & Federal Republic of Nigeria along with the government of India.

Dr. Deepu Banerji MSc, PhD

- Neurosurgeon with over 34 years' experience in microscopic and minimal invasive neurosurgery
- Sugita Fellow from Nagoya University, Japan for micro neuro-surgical training
- Consistently ranked amongst the top 5 neurosurgeons in India.

Dr. Indranil Saha PhD

- Assistant Professor, Computer Science & Engineering, IIT
- Expert in the areas of Artificial Intelligence and Robotics
- Received the ACM SIGBED Frank Anger Memorial Award in 2012 for his contribution in the intersection of embedded systems and software engineering

Dr. Nitin Kadam MBBS, DHC, MD

- Professor at M.G.M. Medical College Mumbai
- Management team member for M.G.M. group of colleges and hospitals
- Director of M.G.M.'s New Bombay Hospital
- Management Council Member, M.G.M. University of Health Sciences, Academic Council & Board of Studies

Dr. Dawn Decunha

- Clinical Psychologist and educator
- Specialty in emotional trauma, psychiatric and psychological trauma

Kiran Kkumari

- Senior oil and gas executive who has assisted some of the largest multinational conglomerates with business development in Asia.

Dr. Navdeep Singh Nanda MBBS, MS, DNB

- One of India's leading thoracic surgeons, practicing in BLK Super Speciality Hospital, the largest stand-alone private sector hospital in India
- Immense experience in the field of thoracic surgery, thoracic oncology, VATS, robotic chest surgery and related research

Dr. Mike Hart MD

- Early adopter of medicinal marijuana applications in medical practice, opening first of its kind facility in London, Ontario
- "Expert" guest on the subject of medicinal marijuana, appearing on CTV news, Rogers TV, CBC National Radio, Toronto Star and Canadian Consortium for the Investigation of Cannabinoids

Dr. Alexander D. Bardon CCFP(EM)

- Emergency Room physician for over 6 years
- Expertise in infectious disease and screening
- Works in 3 different hospital emergency departments: Norfolk General, St. Mary's General and Grand River Hospital
- Associate Clinical Professor at McMaster University

Dr. Tally Bodenstein PhD

- Practicing psychologist for over 20 years
- Speciality in children, adolescents and families



Future Outlook

12~ months

There is a growing need for rapid, mass, early stage screening for governments, healthcare and employers.

We also see that the heightened environment of anxiety caused by the COVID-19 pandemic is accelerating adoption of these technologies.

AI powered technologies such as Predictmedix are positioned to eliminate the need for biologics and can be deployed anywhere without the need for onsite personnel to operate the solution.



Infectious Disease Symptom Screening

- **Proof of Efficacy:** Independent Clinical Validation
- **Expand Revenue Base:** Large scale commercial rollouts in North America, Europe and India, currently in discussion phases
- **Improve Capabilities:** Completion of clinical study with MGM Hospital Group and active data collection and algorithm training to identify symptoms associated with new and emerging COVID variants
- **Multi-Variant Functionality:** Enhancement of AI models using clinical data to further advance multi-symptom detection
- **US Certification:** FDA Class II Medical Device



Drug & Alcohol Impairment Screening


- **Proof of Efficacy:** Independent Clinical Validation
- **Continual Improvement:** Refinement of AI models to improve impairment detection
- **Commercialization of Impairment Functionality:** Pilot programs with partners and new companies to be followed by aggressive commercial rollouts
- **US Certification:** FDA Class II Medical Device



Mobile Wellbeing Remote Care Platform

- **Complete Development:** Completion of upgraded development and sector specific features
- **Customize for Desired Niches:** Launch of platform versions for targeted sectors
- **Initiate Commercialization of AI-Enabled Remote Care Platform:** Pilot and rollout programs





PREDICTMEDIX

CSE : PMED OTCQB : PMEDF

PREDICTMEDIX.COM  

CORPORATE INFORMATION

77 King Street West, Suite 3000
Toronto, ON, Canada M5K 2A1

INVESTOR RELATIONS

Lucas A. Zimmerman
Director – MZ North America
(949) 259-4987
PMEDF@mzgroup.us

